Sanofi India Limited (SANOFI) AI Stock Analysis

• Market Cap: ₹117.33B
• Dividend Yield: 2.3%
• Average Volume (3M): 641.00
• Price to Earnings (P/E): 32.4
• Beta (1Y): 0.76
• Revenue Growth: -23.93%
• EPS Growth: -31.53%
• Country: IN
• Employees: 1,225
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - General
• EPS (TTM): 30.20
• Shares Outstanding: 23,030,000
• 10 Day Avg. Volume: 1,093
• 30 Day Avg. Volume: 641
• PEG Ratio: -1.08
• Price to Book (P/B): 16.38
• Price to Sales (P/S): 7.00
• P/FCF Ratio: 33.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹6,358.00
• Price Target Upside: 24.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: ₹6,358.00 ▲(24.38% Upside)

The overall stock score reflects Sanofi India Limited's strong financial fundamentals and stable cash flow management, which are offset by bearish technical indicators and high valuation metrics. The lack of earnings call data and corporate events limits additional insights into future performance.

Sanofi India Limited Business Overview & Revenue Model

Company Description

Sanofi India Limited operates as a subsidiary of the global healthcare leader Sanofi, with a strong presence in the pharmaceutical sector. The company is primarily engaged in the production and distribution of medicines and consumer healthcare products. Sanofi India focuses on several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and allergies, offering a wide range of prescription medications and over-the-counter products.

How the Company Makes Money

Sanofi India Limited generates revenue through the sale of pharmaceutical products and consumer healthcare products. Its key revenue streams include the production and distribution of prescription medications, which are sold to hospitals, clinics, and pharmacies across India. The company also earns from its consumer healthcare division, offering over-the-counter products that address common health issues. Sanofi India's earnings are bolstered through strategic partnerships and collaborations with healthcare providers and organizations, as well as its investment in research and development to innovate and expand its product offerings. The company's revenue is also influenced by its ability to navigate regulatory environments, market competition, and healthcare policies in India.

Sanofi India Limited Financial Statement Overview

Summary

Sanofi India Limited demonstrates a robust financial position with strong profitability and efficient cash flow management. The balance sheet is stable with low debt levels, although there is revenue and profit margin volatility that needs addressing.

Income Statement

Sanofi India Limited shows a consistent gross profit margin, indicating a stable cost structure. However, the net profit margin has declined from 2023 to 2024, highlighting some challenges in controlling non-operational costs. Revenue growth has been inconsistent, with a notable decrease in 2024 compared to previous years. EBIT and EBITDA margins have also seen fluctuations, reflecting volatility in operational efficiency.

Balance Sheet

The company maintains a very healthy debt-to-equity ratio, demonstrating strong financial leverage management. The equity ratio remains robust, indicating a solid equity base relative to total assets. However, there is a slight decrease in stockholders' equity in 2024, which may warrant monitoring. Overall, the balance sheet reflects financial stability and low risk of over-leverage.

Cash Flow

Sanofi India Limited exhibits strong free cash flow, with an impressive free cash flow to net income ratio, suggesting efficient cash generation relative to earnings. The operating cash flow to net income ratio is solid, indicating good cash earnings quality. While free cash flow growth has been positive, it has shown variability in recent years, requiring attention to sustaining cash flow momentum.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.13B	28.51B	27.70B	29.25B	28.69B
Gross Profit	10.34B	15.94B	15.80B	16.18B	16.15B
EBITDA	4.70B	8.87B	9.08B	13.26B	7.61B
Net Income	4.13B	6.03B	6.21B	9.44B	4.78B
Balance Sheet
Total Assets	16.12B	17.15B	20.72B	30.61B	29.18B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.94B	10.24B	15.38B	11.97B
Total Debt	193.00M	190.00M	236.00M	246.00M	226.00M
Total Liabilities	7.51B	7.00B	7.96B	8.35B	8.00B
Stockholders Equity	8.61B	10.15B	12.76B	22.26B	21.19B
Cash Flow
Free Cash Flow	4.25B	1.96B	3.77B	5.36B	5.70B
Operating Cash Flow	4.62B	2.30B	3.99B	5.59B	6.11B
Investing Cash Flow	-192.00M	375.00M	6.51B	6.31B	2.76B
Financing Cash Flow	-3.92B	-8.78B	-15.83B	-8.49B	-8.10B

Sanofi India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5111.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Negative. The current price of 5111.9 is below the 20-day moving average (MA) of 5649.50, below the 50-day MA of 5915.35, and below the 200-day MA of 5863.88, indicating a bearish trend. The MACD of -228.56 indicates Positive momentum. The RSI at 17.78 is Positive, neither overbought nor oversold. The STOCH value of 3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SANOFI.

Sanofi India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABBOTINDIA	76 Outperform	₹687.25B	47.32		1.44%	9.58%	17.75%
CIPLA	73 Outperform	₹1.23T	22.78		0.85%	6.40%	25.27%
DRREDDY	70 Outperform	₹1.02T	17.92		0.65%	15.76%	2.01%
GLAXO	65 Neutral	₹438.60B	46.16		2.01%	6.65%	48.47%
SANOFI	62 Neutral	₹117.33B	32.37		2.30%	-23.93%	-31.53%
GLENMARK	62 Neutral	₹580.50B	55.43		0.12%	9.39%	―
Sector *	50 Neutral	AU$2.58B	3.16	5.87%	2.68%	36.95%	13.61%

Sanofi India Limited Corporate Events

Sanofi India Reports Growth in Operating Profit Amid Sales Decline

Sanofi India Limited reported a 2% decline in net sales year-to-date but achieved a 6% growth in profit from operations for the period ending June 2025. The company attributes this growth to cost optimization and operational efficiencies. Despite a 9% decline in net sales on a comparable basis, Sanofi India saw strong performance in its diabetes portfolio with the successful launch of Soliqua® and continued growth of Toujeo®. Strategic partnerships in the CV and CNS segments have expanded market reach, although export sales were impacted by the discontinuation of the Zentiva portfolio. The company remains focused on operational excellence and innovation to drive its India strategy.

Sanofi India Limited Announces Financial Results and Leadership Changes

Sanofi India Limited announced the approval of its unaudited financial statements for the quarter and half-year ended June 30, 2025, reflecting compliance with SEBI regulations. The company also disclosed significant management changes, with the retirement of Ms. Renee Amonkar as Whole-time Director and Site Director – Goa, effective August 11, 2025, and the appointment of Mr. Mahadev Gawade as her successor. These changes are expected to impact the company’s leadership dynamics and strategic direction.

Sanofi India Announces Trading Window Closure Ahead of Financial Results

Sanofi India Limited has announced the closure of its trading window from July 1, 2025, until 48 hours after the declaration of its financial results for the quarter and half-year ending June 30, 2025. This move is in compliance with the company’s Code of Conduct to regulate insider trading, ensuring transparency and fairness in the trading of its shares.